{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-024336","form_type":"8-K","ticker":"ADIL","cik":"0001513525","company_name":"ADIAL PHARMACEUTICALS, INC.","filed_at":"2026-03-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.282000+00:00","generated_at":"2026-05-15T18:39:10.877754+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Adial Pharmaceuticals FY2025 net loss $8M, cash $5.9M; advancing AD04 toward Phase 3","bullets":["Net loss of $8.0M in FY2025 vs $13.2M in FY2024, driven by lower R&D and 2024 one-time $4.5M inducement expense.","Cash and cash equivalents $5.9M as of Dec 31, 2025, up from $3.8M; expected to fund operations into H2 2026.","Entered collaboration framework with Molteni for European AD04 commercialization; potential value ~$60M if successful.","Regained Nasdaq minimum bid price compliance on Feb 23, 2026; matter now closed.","Completed EOP2 meeting with FDA; secured U.S. manufacturing partners Cambrex and Thermo Fisher for late-stage development."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-024336","json":"https://secwatch.observer/filing/0001213900-26-024336.json","markdown":"https://secwatch.observer/filing/0001213900-26-024336.md","text":"https://secwatch.observer/filing/0001213900-26-024336.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1513525/000121390026024336/0001213900-26-024336-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1513525/000121390026024336/ea0280282-8k_adial.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T18:39:10.877754+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9dea7862cec38b1c1fe948400a60d83cad80fc60","claim":"ADIAL PHARMACEUTICALS, INC. reported financial results for the 2025 fiscal year ended December 31, 2025.","evidence_excerpt":"On March 6, 2026, Adial Pharmaceuticals, Inc., a Delaware corporation (the “Company”) issued a press release that included financial information for its fiscal year ended December 31, 2025.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1513525/000121390026024336/0001213900-26-024336-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the 2025 fiscal year ended December 31, 2025"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}